Showing 5471-5480 of 8887 results for "".
- Hillstream Enters Into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritishttps://practicaldermatology.com/news/hillstream-enters-into-an-exclusive-option-agreement-to-acquire-a-clinical-stage-asset-for-chronic-pruritis/2461994/Hillstream BioPharma, Inc. is set to acquire AV104 for chronic pruritis. AV104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis. The Company intends to first seek approval in an orphan disease for the treatment of mode
- ABMS Announces Class of 2023-2024 Visiting Scholarshttps://practicaldermatology.com/news/abms-announces-class-of-2023-2024-visiting-scholars/2461993/Gillian Heinecke, MD, an assistant clinical professor at SSM Health/Saint Louis University in St. Louis, Mo. is the American Board of Dermatology’s 2023-2024 Visiting Scholar. The American Board of Medical Specialties (ABMS) selected thirteen outstanding indivi
- The Complexion of Climate in Medical Educationhttps://practicaldermatology.com/news/the-complexion-of-climate-in-medical-education/2461992/The morning news warned us of a heatwave, but that didn’t stop 8-year-old me from putting on my usual red hoodie. The avoidance of prying eyes or hearing “is it contagious?” another time made the sweating worth it. Atopic dermatitis (AD) had claimed my skin as its home, marking
- DermTech Appoints Mark Aguillard as Chief Commercial Officerhttps://practicaldermatology.com/news/dermtech-appoints-mark-aguillard-as-chief-commercial-officer/2461990/Mark Aguillard is DermTech, Inc.’s chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. Prior to joining is DermTech, Mr. Aguillard served as the chief commercial officer of Epic
- Study Sheds Light on Why Wounds Heal Poorly in People With Diabeteshttps://practicaldermatology.com/news/study-sheds-light-on-why-wounds-heal-poorly-in-people-with-diabetes/2461989/When exosomes are defective in diabetic patients, they can drive inflammation and impair healing of wounds, according to a new Nano Today study led by University of Pittsburgh and UPMC researchers
- ICYMI: Vaseline, CVS Partner to Bridge the Gap of Skin Care Inequities in People of Colorhttps://practicaldermatology.com/news/icymi-vaseline-cvs-partner-to-bridge-the-gap-of-skin-care-inequities-in-people-of-color/2461988/Vaseline’s recent Train the Trainer webinar helped educate CVS field leaders on the skin care inequities that exist for Black and Brown populations as part of the brand’s ongoing partnership with CVS Health. During the webcast, Boston area-based dermatologi
- Interim INTEGUMENT-OLE Results: Arcutis’ Roflumilast Cream 0.15% Performs Well in ADhttps://practicaldermatology.com/news/arcutis-roflumilast-cream-015-performs-well-in-ad/2461987/Roflumilast cream 0.15% showed durable and improved efficacy over time and a favorable safety profile in mild to moderate Atopic Dermatitis (AD), according to interim results from the INTEGUMENT-OLE long-term open-label study. Arcutis intends to submit a supplemental New Drug Applicatio
- Meet Secret DUO from Cuterahttps://practicaldermatology.com/news/meet-secret-duo-from-cetera/2461986/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran
- Hoth's Steroid-sparing AD Treatment Shows Promise in Phase 1b Trialhttps://practicaldermatology.com/news/steroid-sparing-ad-treatment-shows-promise-in-phase-1b-trial/2461984/BioLexa led to a 35% improvement in SCORAD ("SCORing Atopic Dermatitis") measurement and a 60% improvement in EASI (Eczema Area and Severity Index) measurement of atopic skin disease during a 14-day treatment period, whereas gentamicin lotion and placebo had no effect, accordi